Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors

Neuropathology

Volumn 30, Issue 6, 2010, Pages 586-596

  Hirose, Takanori ^a,b   Ishizawa, Keisuke ^a   Shimada, Shio ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

1p deletion; Oligoastrocytoma; Oligodendroglioma; P53 protein; TP53

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN P53;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; CYTOGENETICS; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ADULT; AGED; ASTROCYTOMA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; GENE DELETION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; OLIGODENDROGLIOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649538904     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2010.01116.x     Document Type: Article

References (39)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System, 4th edn. Lyon: IARC, 2007.
2. Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Trials Group. J Clin Oncol 1994; 12: 2013-2021.
3. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-1479.
4. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79: 1381-1393.
5. Ueki K, Nishikawa R, Nakazato Y et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201.
6. Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003; 62: 111-126.
7. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007; 131: 242-251.
8. Burger PC, Minn AY, Smith JS et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001; 14: 842-853.
9. Burger PC. What is an oligodendroglioma? Brain Pathol 2002; 12: 257-259.
10. Ueki K. Oligodendroglioma: impact of molecular biology on its definition, diagnosis and management. Neuropathology 2005; 25: 247-253.
11. Kraus JA, Koopmann J, Kaskel P et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91-95.
12. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 2008; 67: 1-15.
13. Smith JS, Perry A, Borell TJ et al. Alterlations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-645.
14. Bauman GS, Ino Y, Ueki K et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000; 48: 825-830.
15. Sasaki H, Zlatescu MC, Betensky RA et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 2002; 61: 58-63.
16. McDonald JM, See SJ, Tremont IW et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 2005; 104: 1468-1477.
17. Scheie D, Cvancarova M, Mork S et al. Can morphology predict 1p/19q loss in oligodendroglial tumours? Histopathology 2008; 53: 578-587.
18. Bigner SH, Matthews MR, Rasheed BKA et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999; 155: 375-386.
19. Watanabe T, Nakamura M, Kros JM et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002; 103: 267-275.
20. Smith JS, Alderete B, Minn Y et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999; 18: 4144-4152.
21. Gelpi E, Ambros IM, Birner P et al. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19a deletion analysis in paraffin-embedded oligodendroglial tumor specimens. Mod Pathol 2003; 16: 708-715.
22. Tanaka Y, Yokoo H, Komori T et al. A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of oligodendroglial phenotype? Acta Neuropathol 2005; 110: 39-47.
23. Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004; 101: 2318-2326.
24. Kelly TW, Tubbs RR, Prayson RA. Molecular diagnostic techniques for the clinical evaluation of gliomas. Diagn Mol Pathol 2005; 14: 1-8.
25. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins P. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-1190.
26. Jeuken JWM, Sprenger SHE, Boerman RH et al. Subtyping of oligo-astorcytic tumours by comparative genomic hybridization. J Pathol 2001; 194: 81-87.
27. Nigro JM, Takahashi MA, Ginzinger DG et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 2001; 158: 1253-1262.
28. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-845.
29. Fuller CE, Perry A. Molecular diagnostics in central nervous system tumors. Adv Anat Pathol 2005; 12: 180-194.
30. Zlatescu MC, Yazdi AT, Sasaki H et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001; 61: 6713-6715.
31. Maintz D, Fiedler K, Koopmann J et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56: 1098-1104.
32. Griffin CA, Burger P, Morsberger L et al. Identification of der(1; 19)(q10; p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65: 988-994.
33. Ligon KL, Alberta JA, Kho AT et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004; 63: 499-509.
34. Yokoo H, Nobusawa S, Takebayashi H et al. Anti-human olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol 2004; 164: 1717-1725.
35. Mokhtari K, Parist S, Aguirre-Cruz L et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol App Neurobiol 2005; 31: 62-69.
36. Kinjo S, Hirato J, Nakazato Y. Low grade diffuse gliomas: Shared cellular composition and morphometric differences. Neuropathology 2008; 28: 455-465.
37. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
38. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
39. Kuhlmann T, Gutenberg A, Schulten H-J, Paulus W, Rohde V, Bruck W. Nogo-A expression in glial CNS tumors. A tool to differentiate between oligodendrogliomas and other gliomas? Am J Surg Pathol 2008; 32: 1444-1453.